TAAR1 Presentations

Trace Amine- Associated Receptors

Program Objectives:

To review trace amines and trace amine-associated receptors and their actions
To discuss mechanisms in how trace amine-associated receptors may modulate neurotransmitters in the brain

and SUMITOMO PHARMA are trademarks of Sumitomo Pharma Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.
© 2023 Sumitomo Pharma America, Inc. All rights reserved.
SUNOVIONMEDICAL.COM

You are now leaving fieldmedicalconnect.com

cancel

continue

Please confirm below to continue:
I confirm that I am a Health Care Professional (HCP) practicing in the United States, or acting on behalf of an HCP.
OR
I am a Formulary Decision Maker (FDM) and/or working on behalf of a public or private payer organization to review scientific information to make drug or device selection or acquisition, formulary management, or coverage and reimbursement decisions on a population basis.

Field Medical Opt-In

First Name* Last Name* Email*

Zip Code State

Click the therapeutic area(s) you would like more information about: Neurology Psychiatry

By clicking submit, I agree and acknowledge that the information I’ve provided voluntarily will be used only by Sumitomo Pharma and its contracted third-parties to contact me regarding my request. I understand that Sumitomo Pharma will not sell or transfer my name to any third party for their marketing use. Please see the most recent version of our privacy notice, which may change from time to time.

*Required

Share this resource

Your Name* Your Email* Your Friend's Name* Your Friend's Email*

Here’s your message:

Please find a link below to Sunovion Health Insights, a website which contains information intended for U.S. fomulary decision-makers only: www.sunovionhealthinsights.com

The information you provide will be used by Sunovion Pharmaceuticals, Inc. in accordance with our Privacy Policy and by parties acting on behalf of Sunovion to send resources. View our Privacy Notice.